CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies

Impact · against what's priced in

CareDx shows strong near-term momentum through 39% Q1 growth and an entry into oncology via the Naveris acquisition, though the long lead time for AlloHeme limits immediate pipeline catalysts. Illumina remains a stable supplier with minimal material impact from this update.

CDNA+0.60

No priced-in read yet

In context

Q1 revenue grew 39% year-over-year with a raised full-year revenue outlook of $447M-$465M. The Naveris acquisition provides an immediate foothold in oncology MRD with projected 30-40% growth over three years, though the primary pipeline priority, AlloHeme, lacks commercial catalysts until 2027.

Read from the article alone

• earnings▲4%
• m and a
• healthcare
• guidance
• ai
• CDNA
• ILMN
• diagnostics
• digital health
• oncology